TabletsTablets
Schedule H (Prescription Required)Urinary Alkalinizers & Stone CareCode: 679

Nalidixic Acid Tablets 500 mg

Generic Formulation:Nalidixic Acid Tablets IP 500 mg
Pack Size:10's
Common Commercial Brand Equivalents:Market reference only
Jan Aushadhi MRP
₹15.94
Brand Estimate*
₹544.52
Estimated Savings:₹528.58 (97% saved)
Find a Kendra Near You
*Statutory price across 21,118 listed Kendras
Clinical InformationReport Error

Clinical Overview

Nalidixic Acid Tablets (500mg) is a first-generation synthetic quinolone antimicrobial on the WHO Model List framework. It selectively inhibits bacterial DNA gyrase (topoisomerase II), blocking bacterial DNA replication and transcription in gram-negative uropathogens including E. coli, Proteus, Klebsiella, and Enterobacter. Indicated for the treatment of acute and chronic uncomplicated urinary tract infections.

Active Pharmaceutical Ingredients

AI-assistedClinical summary synthesized from pharmacopoeial references (CDSCO, WHO EML, IP/BP/USP). Not clinician-reviewed. Drug code 679.Report inaccuracy

Usage Guidelines

Take orally 1 g (two 500 mg tablets) four times daily with a glass of water, with or after meals for 7 to 14 days. Reduce to 500 mg four times daily for prolonged therapy. Maintain adequate fluid intake.

General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.

Possible Side Effects

Common: Nausea, vomiting, abdominal pain, drowsiness, dizziness, photosensitivity reactions. Rare/Severe: Intracranial hypertension (pseudotumor cerebri, bulging fontanelles in infants), seizures, psychosis, and visual disturbances (colors appear halos).

*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.

Precautions & Warnings

Contraindicated in infants under 3 months, history of convulsive disorders, and porphyria. Avoid strong sun exposure due to photosensitivity. Complete the entire course; resistance can emerge rapidly if underdosed.

Schedule H (Prescription Required)

This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.

Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, nephrological diagnosis, or urological treatment recommendations. Always consult a registered nephrologist, urologist, or qualified medical practitioner before initiating, modifying, or discontinuing any kidney or urinary tract medication.